Products & Services > Product Pipeline

The Toxinomics Foundation currently has over 90 molecules in its R&D; pipeline which have been derived from over a dozen different venoms and hemolymphs. The majority were identified within the framework of collaborations within the Foundationís consortium of world-renowned academic experts, with novel molecules being identified on a monthly basis.

The Foundation does not progress assets beyond regulatory filing for use in Phase I, and as a result, our policy is to provide our customers with novel drug candidates accompanied by robust selectivity, mechanism of action, proof-of-concept and preclinical development data alongside full intellectual property coverage and compelling business cases for asset progression. Your success is our success, and our early partnering strategy has been purposely designed to provide you with solid preclinical dossiers that you can trust with high flexibility in terms of the licensing agreements, deal structure and financials linked to a productís acquisition.